Tezted Ltd is innovating the way infectious diseases are diagnosed with a focus on tick-borne diseases and Covid-19.
16/01/2026
SAVE THE DATE | Istanbul, Turkey | September 2026
Join us for the 2nd Annual Conference on Chronic Infection Pathologies (CIP) — From Data to Diagnosis — bringing together clinicians, laboratory scientists, researchers, and patients to advance how we evaluate and manage complex chronic infection and post-infectious conditions.
Conference dates under consideration: Sept 3–6, 2026 (alternate dates: Sept 17–20, 2026)
Pre-conference workshop: Thursday afternoon (½ day) — a hands-on, clinician + lab scientist–led session on diagnostic tools and result interpretation: pros/cons, limitations, “good/bad/ugly,” and best-practice approaches.
Key topics include: Lyme disease, Long COVID, and infectious disease challenges of the 21st century.
Interested in attending, presenting, or sponsoring? Email: info@chronicinfectionpathologies.com
31/12/2025
Happy New Year! Te?ted Oy - Tezted
25/12/2025
Happy Holidays Te?ted Oy - Tezted
24/12/2025
Happy Holidays and Merry New Year! Te?ted Oy - Tezted
10/12/2025
Human rights are not a luxury. They are our everyday essentials.
This Human Rights Day 2025, we stand behind the theme: “Human Rights, Our Everyday Essentials” – a powerful reminder that dignity begins with the basics:
Clean water and safe sanitation
Quality education for every child
Accessible healthcare for all
Freedom of expression and participation
These are not optional. They are the foundation of fair, just, and thriving societies.
As we mark Human Rights Day, let’s ask ourselves:
What can I do today to defend someone’s right to learn, to be heard, to be safe, or to be healthy?
Change starts in our homes, workplaces, schools, and communities. When we protect these everyday essentials for others, we protect them for ourselves too.
Human rights are not abstract ideals – they are the conditions that make everyday life livable.
10/12/2025
Exciting news! Our latest research on Lyme and Lyme-like illness in Australia has just been accepted for publication in the journal Pathogens.
Using a test called TICKPLEX®, two independent labs (one in Finland and one in Australia) analysed blood samples from people with suspected tick-borne diseases and from international Lyme reference panels. We found that:
The test produced consistent results between the two laboratories, and
Australian samples showed immune responses to multiple microbes linked to tick-borne infections and related opportunistic infections.
What does this mean?
It suggests that broader, multiplex testing may help reduce missed or misdiagnosed tick-borne disease cases in Australia, especially for people with long-lasting, debilitating symptoms after tick bites.
We are grateful to everyone involved in this work and to the patients and clinicians who continue to push for better recognition, diagnostics and care.
We’ll share the full open-access article link here as soon as it’s available – stay tuned!
Garg K, Villavicencio-Aguilar F, Solano F, Gilbert L. Interlaboratory Concordance of a Multiplex ELISA for Lyme and Lyme-like Illness: A Proof-of-Concept Study Using Australian Samples and U.S.A/European Lyme Reference Sera. 2025 Pathogens 3967588, in press.
09/12/2025
New Evidence on COVID-19 mRNA Vaccines and Mortality
A French nationwide study of nearly 29 million adults (ages 18–59) provides reassuring long-term data:
• 25% lower all-cause mortality in vaccinated individuals (Figure: Cox model analysis, wHR 0.75).
• 74% lower risk of COVID-19 death (Table 2: 18 vs 85 deaths per million).
• Reduced deaths from cancer, circulatory disease, and external causes.
• Short-term safety confirmed: mortality was 29% lower within 6 months post-vaccination (Supplementary eFigure 5).
📊 These findings, published in JAMA Network Open, reinforce that vaccination not only protects against COVID-19 but is associated with broader survival benefits.
👉 Read the full study: JAMA Network Open
Semenzato L, Le Vu S, Botton J, et al. COVID-19 mRNA Vaccination and 4-Year All-Cause Mortality Among Adults Aged 18 to 59 Years in France. JAMA Netw Open. 2025;8(12):e2546822. doi:10.1001/jamanetworkopen.2025.46822
27/11/2025
Happy Thanksgiving!
14/11/2025
Exciting news from !
Innovation, collaboration, and cutting-edge insights are taking center stage as leaders and experts come together to shape the future of Lyme disease research and technology.
Proud to be part of an event driving meaningful progress and empowering the community with knowledge and solutions.
24/10/2025
On 5-7 September we hosted the 🧬 1st Annual Conference on Chronic Infection Pathologies – SHOW ME THE DATA! 🧬 in Jyväskylä of Finland.
🌐 150 participants, both online and onsite, from 16 different countries gathered to explore the current landscape of treatment and research related to chronic illnesses.
📊 We had the opportunity to witness 26 enlightening presentations that underscored the importance of events like the CIP Conference.
💔 A concerning trend emerged from the shared data: Chronic Infections remain largely unrecognized globally, leaving many patients without adequate treatment.
🌱 At CIP, our goal is to UNITE primary care providers, patients, and scientists to raise awareness about these complex and challenging diseases.
☀️ A heartfelt THANK YOU to all our attendees for coming together to exchange knowledge and experiences. Many new connections were made, and we look forward to seeing how you continue to improve the lives of those affected by chronic infection diseases.
✨ Stay tuned for our upcoming posts, where we will share more highlights from the Conference. ✨
Tiedä ensimmäisenä ja anna meille oikeus lähettää sinulle sähköpostitse uutisia ja promootioita Te?ted Oy - Tezted :ltä. Sähköpostiosoitettasi ei käytetä muihin tarkoituksiin, ja voit perua milloin tahansa.
Lets get the patient tested so they can be treated and recover quicker
Tickplex Validation Process
Te?ted Oy is a university spin off company from research work conducted under Dr. Leona Gilbert, and Te?ted Oy is now manufacturing and selling to clinical laboratories TICKPLEX Products. TICKPLEX in itself was a research project at under Dr. Leona Gilbert’s research team from July 2015 to Sept 2016 funded by the Finnish Funding Agency for Innovation, (Finnish Government) now called Business Finland. Within this project we have scientifically validated the test kit as reported in the “Validation Paper” and also peer reviewed in the Nature's Scientific Reports paper found at this site https://www.nature.com/articles/s41598-018-34393-9
As soon as Te?ted Oy was established, TICKPLEX Products, (Basic and Plus test kits) underwent an additional scientific and clinical validation according to all appropriate laws; EU IVD Directive (In vitro diagnostic medical devices directive) 98/79/EC and the Finnish Medical Device Law Regarding Healthcare, Devices and Supplies 2010/629 that lead to its IVD CE conformity declaration. Our test kits also conformed as declared to the following relevant harmonized standards used of references to the other technical specifications in relation to which conformity is declared:
- SFS-EN ISO 14971 Medical devices. Application of risk management to medical devices.
- SFS-EN 13612n + AC Performance evaluation of in vitro diagnostic medical devices.
- SFS-EN ISO 23640 In vitro diagnostic medical devices. Evaluation of stability of in vitro medical
reagents.
- SFS-EN ISO 18113-1 In vitro diagnostic medical devices. Information supplied by the
manufacturer (labelling). Part 1: terms, definitions and general requirements.
- SFS-EN-ISO 18113-2. Part 1: terms, definitions and general requirements.
- SFS-EN 15223-1:2016 Medical devices. Symbols to be used with medical device label, labelling and information supplied. Part 1: General requirements.
These products are registered with the national regulatory authorities here in Finland as ascribed by the law. In addition, the national regulatory authority conducted a routine inspection and found that we are conducting business and manufacturing according to the laws. Te?ted Oy company even went further to provide credibility with its processes and manufacturing and was accredited ISO 13485:2016 qualification through an external auditor, Lloyd’s Register LRQA. In order for any clinical lab to start selling our test kits, they have to independently validate the test kit as directed by the law, EU IVD Directive 98/79/EC. It is the law which means that this test kit has been independently validated. At the moment TICKPLEX Products have been validated independently in clinical laboratories that have expertise in diagnosing tick-borne diseases, in Germany, Poland, Netherlands, USA and Finland. All the best Te?ted Oy Team
